Dual Purpose Anti-Viral, Vermifugal Formula
Veterinary Formula with Experimental Uses
Contains Botanicals With Ivermectin
Code IVY-1 / 100 Capsules x 200 mg. / Price: $14.95
Each capsule contains 3 mg. of Ivermectin
[In jurisdictions where allowed for adult use:
Normal adult dosage: 1 to 4 capsules, depending
on condition and weight (see below). For ages
12 years and older. Keep out of children's reach].

(Sent by courier direct from Thailand)

vermectin is a broad-based, anti-parasitic medication that is approved worldwide for treatment in both humans and animals. In fact, it is on the WHO Model List of Essential Medicines.
Discovered in 1975, it came into medical use in 1981. It is widely used to treat head lice, river blindness (onchocerciasis), helminthiases, scabies, strongyloidiasis, trichuriasis, ascariasis, and lymphatic filariasis, among others.
Despite its widespread use by parasitologists, most people had never heard of ivermectin until claims began to surface earlier this year (2021) that ivermectin -- this FDA-approved anti-parasitic drug -- can "kill" the coronavirus within 48 hours. [Perhaps deactivate would be a better way to put it, since viruses are not "alive." They're exosomes created by the body itself in response to a toxic or nutrient-deficient (usually Vitamin D or zinc) condition.] A variety of professional medical groups have implored the CDC and FDA in the States to review Ivermectin research as it relates to CoVid. Instead of reviewing the research, the FDA, for its part, has warned against using ivermectin to treat CoVid, despite the fact that in India, the second most populated country in the world, ivermectin is being successfully used to treat health care workers. In fact, research groups who are not politically aligned to pharmaceutical or vaccine industry interests are reporting that ivermectin is effective in both treating and preventing the CoVid. One Latin-based group of physicians has reported curing over CoVid 6,000 patients using ivermectin. (Their words, not ours.) In the Dominican Republic, three clinics collectively reported that 99.3% of COVID-19 patients treated with Ivermectin recovered in five days. A physician in Milwaukee, testified before a U.S. Senate hearing that ivermectin is a "wonder drug."
These are important discoveries, especially in light of the enormous amount of fraud that is surfacing regarding CoVid reporting. (Example: The CDC, a vaccine industry advocate, not an independent government agency, has recently had to admit that at least 96% of deaths from CoVid were deliberately misreported. (Medical institutions throughout the system have been financially incentivized to lie about "cause of death" among its patients.) Naturally, if conventional institutions are incapable of being honest about something as readily determinable as "cause of death," they are not going to be honest about reporting which drugs or therapeutic approaches actually work.

Ivermectin: Miracle Cure for CoVid -- Here we see expert testimony by Dr. Pierre Kory, M.D. before a Senate subcommittee hearing. Testifying under oath, Dr. Kory makes the argument that given all the evidence collected to date on the use of ivermectin to treat CoVid, this long-established vermifugal is nothing short of a "miracle cure." (Runs 7:35).

"Anti-Paravites": A Different Approach
What we've done is combine botanicals which exert the most efficacious effects against viral conditions, together with ivermectin. The properties of each is well-established: Pau d'arco (Handroanthus impetiginosus): Antiinflammatory, antiparasitic, antiviral, and bacterocidal; chanca piedra (Phyllanthyus niruri): Antiinflammatory, antiviral, hepatoprotective, vermifugal; anamu (Petiveria alliacea): Antiinflammatory, antiviral, vermifugal; samambaia (Polypodium decumanum): Antiinflammatory, antiviral, vermifugal; pharmaceutical-grade ivermectin (1.5% or 3 mg. per 200 mg. capsule): Antiinflammatory, antiviral, and vermifugal.

The following protocols (for adult human use) are established and widely used by conventional practitioners -- (source: drugs.com.)
  1. Onchocerciasis: 0.15 mg/kg orally once every 12 months. Patients with heavy ocular infection may require retreatment every 6 months. Retreatment may be considered at intervals as short as 3 months. Dosage guidelines based on body weight:

    -- 15 to 25 kg: 3 mg orally one time
    -- 26 to 44 kg: 6 mg orally one time
    -- 45 to 64 kg: 9 mg orally one time
    -- 65 to 84 kg: 12 mg orally one time
    -- 85 kg or more: 0.15 mg/kg orally one time

  2. Strongyloidiasis: 0.2 mg/kg orally once. In immunocompromised (including HIV) patients, the treatment of strongyloidiasis may be refractory requiring repeated treatment (i.e., every 2 weeks) and suppressive therapy (i.e., once a month), although well-controlled studies are not available. Cure may not be achievable in these patients.

    -- 15 to 24 kg: 3 mg orally one time
    -- 25 to 35 kg: 6 mg orally one time
    -- 36 to 50 kg: 9 mg orally one time
    -- 51 to 65 kg: 12 mg orally one time
    -- 66 to 79 kg: 15 mg orally one time
    -- 80 kg or more: 0.2 mg/kg orally one time

  3. Ascariasis: 0.2 mg/kg orally once

  4. Cutaneous Larva Migrans: .2 mg/kg orally once

  5. Filariasis: 0.2 mg/kg orally once

  6. Scabies: 0.2 mg/kg orally once, and repeated in 2 weeks

The most common protocol for prophylaxis appears to call for "ivermectin, 12 mg. (the equivalent of 4 capsules of Anti Paravites on day 1, day 7 and day 30, with or after meals, followed by one tablet or capsule of 12 mg. every 48 hours, for prophylaxis if risk is a concern."

Ivermectin & CoVid -- Admittedly, the delivery is dry and clinical, but if you stay through to the end of this 10 minute video, you'll find that the results being obtained for both the prevention and treatment of CoVid being reported worldwide is both substantial and encouraging .

Our view is that the benefits of ivermectin are conclusive -- not only as a vermifuge, for which regulatory agencies, like the FDA, originally approved the drug, but also for a wide range of viral conditions, including CoVid-19. However, our concern is that there is a possibility that drugs like ivermectin and hydrochloroquine will obscure the necessity to cover the essentials first. For example, in our page entitled, Coronavirus: Essential Self-Defense Against Infection, we make it clear that deficiencies in certain nutrients, including Vitamin D, Vitamin C, magnesium, and zinc can worsen, if not be a contributing cause, to the condition we now call CoVid. We believe it is an errancy to reach for an anti-viral -- be it pharmaceutical, a natural botanical -- of which Anti Paravites contains both, if you haven't covered nutritional deficiencies first.
If you have covered nutritional deficiences and a viral condition still exists, then Anti Paravites can be of tremendous benefit in helping to eradicate the condition.

Postscript: Updates
Since this page was first composed and posted, a mountain of additional data and articles about Ivermectin have poured in. Below, we post some of the more noteworthy:
Ingredients: Pau d'arco (Handroanthus impetiginosus), chanca piedra (Phyllanthyus niruri), anamu (Petiveria alliacea), samambaia (Polypodium decumanum), pharmaceutical-grade ivermectin (1.5% or 3 mg. per 200 mg. capsule).

The label is marked as veterinary vermifuge.

Key Links

Studies & Commentaries
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen -- (Sept., 2020) -- Abstract: Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness -- (Feb., 2021) -- Abstract: Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. . .
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin -- (Jan., 2021) -- Abstract, Partial: As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence varies greatly among different countries. These differences raise the question whether nations with a lower incidence share any medical commonalities that could be used not only to explain that lower incidence but also to provide guidance for potential treatments elsewhere. Such a treatment would be particularly valuable if it could be used as a prophylactic against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission, thereby effectively slowing the spread of the disease while we await the wide availability of safe and effective vaccines. Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19. Prophylactic use of ivermectin against parasitic infections is most common in Africa and we hence show that the reported correlation is highly significant both when compared among African nations as well as in a worldwide context. We surmise that this may be connected to ivermectin's ability to inhibit SARS-CoV-2 replication, which likely leads to lower infection rates. However, other pathways must exist to explain the persistence of such an inhibitory effect after serum levels of ivermectin have declined.
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis -- (Mar., 2021) -- Objective: The effect of ivermectin on mortality in patients with novel coronavirus disease 2019 (COVID-19) has been investigated in many studies. We aimed to perform a meta-analysis of randomized controlled trials to investigate the overall effect of ivermectin on the risk of mortality in patients with COVID-19. (Six randomized controlled trials were included in this analysis with a total of 658 patients who were randomized to receive ivermectin and 597 patients randomized in the control group who did not receive ivermectin.) Results: We observed a preliminary beneficial effect on mortality associated with ivermectin use in patients with COVID-19. . .
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study -- (Feb., 2021) -- Background: Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 mcg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.
Global trends in clinical studies of ivermecetin in CoVID-19 -- This 52 page report covers a variety of studies involving ivermectin in the treatment of CoVid. The results are a mixed bag. On page 39, in the Conclusion section, the paper clearly states, "there are many study reports demonstrating that the administration of a normal dose does indeed show a clinical response. As of the 27th of February 2021, the results of 42 clinical studies worldwide have undergone meta-analysis and concluded that ivermectin is effective in the treatment and prevention of COVID-19. In the UK, a consensus-based recommendation by 75 healthcare professionals from 17 countries around the world has been carried out and submitted to the WHO to further encourage the issuance of guidelines for the use of ivermectin in the treatment and prevention of COVID-19. However, what precedes this is an arcane discussion of blood concentration levels, meant to infer that maybe ivermectin isn't so effective after all. Politics overriding scientific fact. Yet again. This is why people have lost faith in scientific studies, just as they have lost people in these same people, who knowingly foisted CoVid upon the unsuspecting world.
Physician slams YouTube's 'extremely misguided' decision to pull Senate testimony about COVID treatment -- In the main column at left, you'll find a video link to testimony by Dr. Pierre Kory, the president of the Front Line CoVid-19 Critical Care (FLCCC). In this article, Kory explains what a travesty it was that his Senate testimony about CoVid treatment was taken down by YouTube -- unquestionably to make the trillion dollar vaccine makers happy.

Wikipedia does hit piece on Dr. Pierre Kory, President of the FlCCC -- I've been complaining about the tyrannical nature and truth-destroying tactics of Wikipedia for years. So it only makes sense that Wikipedia would do a hit-piece on Dr. Kory after his ivermectin testimony before the U.S. Senate last December (2020). Can't possibly let truth or facts get in the way of the diabolical goal of fulfilling Bill Gates' vision of a sterilized, human-free planet.

Lectures like this 28 minute segment are becoming more common where physicians are warning the public about the need for Vitamin D and zinc in the fight against CoVid and other viral conditions. An excellent presentation here is made regarding the value of ivermectin around 14:25 -- but this should be viewed within the context of the rest of the video. Predictably, Facebook's lying "fact checkers" are pooh-poohing this presentation, so I don't expect it to stay up for long.

Ivermectin has a number of potentially serious drug-drug interactions. Please check for potential drug interaction at Ivermectin Drug Interactions - Drugs.com. The most important drug interactions occur with cyclosporin, tacrolimus, anti-retroviral drugs, and certain anti-fungal drugs.
Due to the possible drug interaction between quercetin and ivermectin (may increase ivermectin levels), these drugs should not be taken simultaneously (i.e. should be staggered morning and night). Ivermectin is also lipophilic and therefore, bioavailability is maximised on a full stomach; or best to be taken with meal.